Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2463 studies found for:    OVARIAN CANCER
Show Display Options
Rank Status Study
1 Active, not recruiting Masitinib in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Masitinib (AB1010);   Drug: Gemcitabine
2 Unknown  Oxford Ovarian Cancer Predict Chemotherapy Response 01
Condition: Ovarian Cancer
Intervention:
3 Active, not recruiting SGI-110 in Combination With Carboplatin in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: SGI-110 and carboplatin;   Drug: Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)
4 Recruiting Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Condition: Ovarian Cancer
Intervention: Drug: pazopanib in combination with weekly topotecan
5 Terminated Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: lapatinib
6 Completed
Has Results
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Sorafenib;   Drug: Paclitaxel;   Drug: Carboplatin
7 Terminated Weekly Topotecan Therapy in Patients With Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Topotecan
8 Completed Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Imatinib Mesylate;   Drug: Docetaxel
9 Completed A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: ABT-888;   Drug: pegylated liposomal doxorubicin;   Drug: temozolomide
10 Unknown  Hydralazine Valproate for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Hydralazine and magnesium valproate;   Drug: Placebo
11 Completed p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: P53-SLP vaccine;   Drug: Cyclophosphamide
12 Completed
Has Results
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Docetaxel;   Drug: Carboplatin
13 Terminated NYU Ovarian Cancer Early Detection Program Blood and Genetics
Condition: Ovarian Cancer
Intervention:
14 Terminated Cabazitaxel in Platinum Refractory Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Cabazitaxel
15 Completed Risk of Ovarian Cancer in Patients With a Pelvic Mass
Condition: Ovarian Cancer
Intervention: Device: Biomarker Assay (CA125 and HE4)
16 Completed
Has Results
Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Bendamustine HCL
17 Completed
Has Results
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Pertuzumab (rhuMAb 2C4)
18 Completed The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention:
19 Active, not recruiting Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Condition: Ovarian Cancer
Intervention: Drug: IMAB027
20 Terminated
Has Results
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Biological: Abagovomab;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.